Manufacturer
BAXTER PHARMACEUTICAL SOLUTIONS LLC,
Contents
Golimumab
Indication
Rheumatoid arthritis, Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, Psoriatic arthritis, Juvenile idiopathic arthritis, Ulcerative colitis
Instruction
IV RA, AS 2 mg/kg as 30-min infusion at wk 0 & 4, then every 8 wk thereafter. SC RA, PsA, AS & nr-Axial SpA 50 mg inj once a mth (same date each mth). Patient >100 kg w/ inadequate clinical response after 3 or 4 doses May increase dose to 100 mg once a mth. Ulcerative colitis Patient ≥80 kg Initially 200 mg, followed by 100 mg at wk 2, then 100 mg every 4 wk, <80 kg Initially 200 mg, followed by 100 mg at wk 2, then 50 mg every 4 wk.
Drug interaction
Not recommended w/ concurrent use of anakinra, etanercept, abatacept & other biological therapeutics. Not to be given concurrently w/ live vaccines. Higher steady-state trough conc w/ SC MTX.
Malaysia
